OncoMatch/Clinical Trials/NCT06973187
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Is NCT06973187 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including BGB-16673 and Pirtobrutinib for chronic lymphocytic leukemia.
Treatment: BGB-16673 · Pirtobrutinib — The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Chronic Lymphocytic Leukemia
Prior therapy
Must have received: covalent bruton tyrosine kinase inhibitor
Cannot have received: bruton tyrosine kinase protein degrader
Cannot have received: noncovalent bruton tyrosine kinase inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Phoenix · Phoenix, Arizona
- University of California San Diego (Ucsd) Moores Cancer Center · La Jolla, California
- UCLA Department of Medicine Hematologyoncology · Los Angeles, California
- Stanford Cancer Institute · Palo Alto, California
- Christiana Care · Newark, Delaware
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06973187 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bruton tyrosine kinase protein degrader, noncovalent bruton tyrosine kinase inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages